This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy To Board Of Directors

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced the appointment of Matthew Duffy to its Board of Directors.

Mr. Duffy has extensive pharmaceutical experience which includes early stage product development through the launch of several large marketed products. Mr. Duffy began his career at Pfizer, Inc. holding a series of executive positions in sales, marketing and product management. At Pfizer, he worked on over 10 different pharmaceutical products, including treatments for depression, diabetes, infectious diseases, urologic disorders and hypertension. Mr. Duffy was the first product manager for Viagra ®. Mr. Duffy led the marketing group at MedImmune, Inc. from 1995 to 2001, where he was responsible for the launch of both RespiGam and Synagis for the prevention of respiratory disease in premature infants, as well as new indications for CytoGam in the transplantation field. Synagis sales have exceeded $1 billion. In addition to working on various product launch efforts, Mr. Duffy also was responsible for market and product evaluations for MedImmune’s development pipeline, as well as the company’s customer service call center. Mr. Duffy led commercial operations at Lev Pharmaceuticals, overseeing launch preparations for Cinrzye, an Orphan Drug for the treatment of hereditary angioedema, including forming the sales team, developing the marketing plan, distribution plan, managed care strategy and patient services infrastructure. Currently Cinryze has annualized sales over $250 million.

He is currently a managing partner and founder of Black Diamond Research, LLC, which was an independent sell-side research firm specializing in healthcare and currently provides consulting services to industry. Mr. Duffy received his undergraduate degree from Duke University. He holds the series 7, 63 and 65 securities licenses. Mr. Duffy is also a managing member of NSIP LLC; member, and member of the Executive Committee of Ellington Asset Management, LLC, a healthcare focused venture capital fund.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.12 -1.80%
FB $116.48 -0.21%
GOOG $691.78 0.11%
TSLA $238.00 -3.90%
YHOO $36.36 -0.63%


Chart of I:DJI
DOW 17,685.20 -145.56 -0.82%
S&P 500 2,055.98 -19.83 -0.96%
NASDAQ 4,759.3580 -45.9330 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs